Evidence map›Paper›PMID 36185295›Full record

ReviewFrontiers in oncology2022

The role transition of radiotherapy for the treatment of liver cancer in the COVID-19 era.

Zheng Li, Yue Hu, Ming Zeng, Qinyong Hu, Fei Ye, Ruifeng Liu, Hongyi Cai, Qiang Li, Xiaohu Wang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Zheng LiInstitute of Modern Physics, Chinese Academy of Sciences, Lanzhou, China.
Yue HuChengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Ming ZengDepartment of Radiation Oncology, MetroHealth Medical Center, Case Western Reserve University, Cleveland, OH, United States.
Qinyong HuCancer Center, Renmin Hospital of Wuhan University, Wuhan, China.
Fei YeInstitute of Modern Physics, Chinese Academy of Sciences, Lanzhou, China.
Ruifeng LiuInstitute of Modern Physics, Chinese Academy of Sciences, Lanzhou, China.
Hongyi CaiDepartment of Radiotherapy, Gansu Provincial Hospital, Lanzhou, China.
Qiang LiInstitute of Modern Physics, Chinese Academy of Sciences, Lanzhou, China.
Xiaohu WangInstitute of Modern Physics, Chinese Academy of Sciences, Lanzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The uncontrollable COVID-19 crises in the SARS-CoV-2 high-prevalence areas have greatly disrupted the routine treatment of liver cancer and triggered a role transformation of radiotherapy for liver cancer. The weight of radiotherapy in the treatment algorithm for liver cancer has been enlarged by the COVID-19 pandemic, which is helpful for the optimal risk-benefit profile.

Indexed as

artificial intelligenceCOVID-19liver neoplasmsmedical resourceradiotherapySARS-CoV-2telemedicine

Identifiers

PMID36185295
PMCPMC9516283

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.